For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...

Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.

When it comes to bladder cancer, it’s important to note the differences between muscle-invasive and non-muscle-invasive bladder cancer, as it can affect the staging of the cancer. The “stage” (spread) ...

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s cisplatin eligibility.

Merck’s Keytruda is riding a winning streak in bladder cancer. Following FDA approvals in the metastatic and non-muscle invasive settings, the anti-PD-1 therapy has delivered a positive readout in ...

UroGen Pharma (URGN) announced that adult patients living with recurrent low-grade intermediate-risk non-muscle invasive ...

Senior male patient in hospital gown seen through CAT scan machine. Male patient at clinic for MRI scan. The 2023 guideline on managing muscle-invasive bladder cancer offers evidence-based ...